Electrocore Stock Price, News & Analysis

electroCore anticipates record revenue of at least $2.1 million for Q2 2022, representing a 65% increase from Q2 2021. This guidance indicates an 11% rise over Q1 2022 revenue. Key revenue sources include approximately $1.2 million from government channels, $465,000 from commercial sales, and $466,000 from international markets. The company's cash balance at the end of Q2 2022 stands at $26.6 million. A detailed financial update is expected in August.

electroCore (Nasdaq: ECOR) announced that Mayo Clinic is initiating a study on gammaCore Sapphire, a non-invasive vagus nerve stimulation therapy, to evaluate its efficacy in treating post-COVID syndrome. The study aims to enroll up to 20 patients with symptoms persisting over 28 days post-COVID infection. The trial will assess clinical questionnaires and brain metabolism using PET-CT. This follows gammaCore’s past FDA approval for treating migraines and cluster headaches, suggesting its relevance in addressing post-COVID health issues that may affect millions globally.

electroCore, Inc. (Nasdaq: ECOR) announced it has received approval from Nasdaq to transfer its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective June 23, 2022. This move follows a notification regarding noncompliance with the minimum bid price requirement. The company is granted an additional 180 days to regain compliance with the closing bid price of at least $1.00 per share. electroCore focuses on bioelectronic medicine, particularly in treating conditions like migraines and cluster headaches.

On May 24, 2022, electroCore (Nasdaq: ECOR) announced that its gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available at over 130 National Spine and Pain Centers (NSPC) locations across the U.S. This partnership aims to enhance patient access to non-opioid pain management solutions for primary headaches. Mitch DeShon from electroCore emphasized the importance of collaboration with NSPC to improve treatment outcomes, while NSPC's mission focuses on alleviating unnecessary pain through innovative therapies. GammaCore is FDA cleared and CE-marked for various headache treatments.

electroCore, Inc. (Nasdaq: ECOR) announced that CEO Dan Goldberger will present at two upcoming conferences. The H.C. Wainwright Global Investment Conference is scheduled for May 24, 2022, at 7:00 AM EDT, with a webcast available. The LD Micro Invitational Conference will take place on June 7, 2022, at 10:30 AM PDT, also offering a livestream. After the events, presentation replays will be accessible on the company’s investor website. electroCore focuses on non-invasive vagus nerve stimulation therapies for neurological conditions.

electroCore (Nasdaq: ECOR) reported first-quarter 2022 net sales of $1.9 million, marking a 58% increase over the same period in 2021 and a 27% increase sequentially. The company used $4.8 million in operating cash, ending the quarter with $29.9 million in cash and equivalents. Notable developments include the launch of a U.S. e-commerce portal for gammaCore™ therapy, receiving FDA Breakthrough Device Designation for PTSD treatment, and signing an exclusive licensing agreement with Teijin for Japan.

electroCore, Inc. (Nasdaq: ECOR) will report its first quarter financial results on May 5, 2022, after market close. A conference call and webcast are scheduled for 4:30 PM EDT to discuss these results. The company specializes in bioelectronic medicine, focusing on non-invasive vagus nerve stimulation therapies for conditions like migraines and cluster headaches.

electroCore, Inc. (Nasdaq: ECOR) has announced the successful completion of the sale of its tax benefits through the New Jersey Economic Development Authority’s program for fiscal year 2021. The company received approximately $445,000 in non-dilutive cash from selling its net operating loss (NOL) tax benefits. This marks the third consecutive year of benefiting from this program, which supports investment in sales and marketing to enhance awareness of its product gammaCore. The NOL program aids eligible NJ-based tech companies by converting tax losses into cash for operational funding.

electroCore, Inc. (Nasdaq: ECOR) announced the publication of the SAVIOR-1 trial results in Frontiers in Neurology, evaluating non-invasive vagus nerve stimulation (nVNS) therapy in COVID-19 patients. Conducted from April 2020 to February 2021, the trial involved 110 patients and highlighted significant decreases in inflammatory biomarkers, such as C-reactive protein (CRP) and procalcitonin, in the nVNS group. With no major adverse events reported, the findings suggest nVNS may improve COVID-19 symptoms alongside standard care, potentially validating the technology's relevance.